Vitiligo
☆ Vo výsledkoch Stiftung Warentest z Nemecka za rok 2022 bola spokojnosť spotrebiteľov s ModelDerm len o niečo nižšia ako s platenými telemedicínskymi konzultáciami.
Vitiligo prstov sa lieči ťažšie ako iné oblasti. Okrem toho, že je kozmeticky nevzhľadné, vitiligo je normálne a nie je nákazlivé. V dermatológii je najúčinnejšia liečba fototerapia alebo laserové ošetrenie (excimer) 2-3x týždenne po dobu minimálne 1 roka. Ak nemôžete často chodiť do nemocnice z finančných dôvodov alebo pre zaneprázdnenosť, môžete vyskúšať fototerapeutický prístroj, ktorý je schválený na domáce použitie.
Vitiligo očných viečok
Vitiligo po ruke
References
Vitiligo je bežná kožná porucha, ktorá spôsobuje škvrny bielej kože v dôsledku straty melanocytov. Nedávny výskum ukazuje, že ide o autoimunitné ochorenie. Aj keď sa to často považuje za kozmetický problém, môže hlboko ovplyvniť duševnú pohodu a každodenný život. V roku 2011 odborníci klasifikovali typ s názvom segmental vitiligo oddelene od ostatných.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Pacienti s aktívnym vitiligom majú niekoľko možností terapie, ako sú systémové glukokortikoidy, fototerapia a systémové imunosupresíva. Pacienti so stabilným vitiligo môžu nájsť úľavu od lokálnych kortikosteroidov, lokálnych inhibítorov kalcineurínu, fototerapie a transplantačných procedúr. Nedávny pokrok v chápaní základných procesov vitiliga viedol k vývoju cielených terapií. V súčasnosti sú najsľubnejšie inhibítory JAK, ktoré ponúkajú dobrú znášanlivosť a funkčné výsledky, napriek riziku aktivácie latentných infekcií a systémových vedľajších účinkov, ktoré sú bežné u iných imunosupresív. Prebiehajúci výskum sa zameriava na identifikáciu kľúčových cytokínov podieľajúcich sa na rozvoji vitiliga (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Blokovanie týchto cytokínov sa ukázalo ako sľubné na zvieracích modeloch a u niektorých pacientov. Okrem toho prebiehajú vyšetrovania miRNA-based therapeutics a adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Nie je známy žiadny liek na vitiligo. Pre ľudí so svetlou pokožkou sa zvyčajne odporúča opaľovací krém a make-up. Ďalšie možnosti liečby môžu zahŕňať steroidné krémy alebo fototerapiu.
○ Liečba
#Phototherapy
#Excimer laser
#Tacrolimus ointment